Alzheimer's Drug Discovery Foundation

The ADDF has appointed Isobel Coleman as Chief Executive Officer. A global leader across government, nonprofit & private sectors, she will guide the next era of Alzheimer’s research, advancing combination therapies & precision medicine. Read more: bit.ly/4lkx4B2

New Phase 2 results from @biogen's CELIA study of #BIIB080 mark an encouraging step toward targeting Alzheimer’s beyond amyloid, reinforcing #tau as a promising target and highlighting momentum toward next-generation therapies. bit.ly/438aL9k

Today, #Fujirebio received CE Marking in the European Union for its ADDF-funded pTau217 test, following FDA approval in the U.S. The milestone reflects growing global momentum behind scalable, validated biomarkers and a broader shift in the field. bit.ly/4uftuMf

The 16th annual Great Ladies Luncheon raised a record-breaking $850,000 for Alzheimer's research at The Ritz-Carlton DC. Read the full story on The Washington Lobbyist: thewashingtonlobbyist.com/great-ladies-l… #DCFashionEvents #ADDFLadiesLuncheon @TheADDF #GreatLadiesLuncheon #BrainHealth

Alzheimer's disease drug development pipeline: 2026 published today! The 2026 AD drug development pipeline includes 158 unique therapies in 192 trials, marking continued growth in disease-modifying agents, with 35% being repurposed drugs. Thanks @DrJeffCummings @NIHAging @TheADDF

The Alzheimer’s Drug Development Pipeline 2026 Report reveals that treating the underlying biology is driving the next gen of therapies—75% of drugs target novel aging pathways, paving the way for combination therapy & precision medicine. @DrJeffCummings bit.ly/4tRKsjF

“Clean” nicotine is being marketed as a brain boost. ADDF’s Yuko Hara shares with @AARP that questions remain about safety and addiction potential. While nicotine may offer short-term cognitive effects, it also comes with risks. bit.ly/4d2KyxQ

Exercise, nutrition & social engagement are core components of supporting cognitive health in aging populations. The future lies in precision prevention, integrating lifestyle & therapeutic interventions tailored to each person, similar to heart disease. nbcnews.to/4tlcyn4

Dinner with the new @TheADDF CEO, what a fantastic lady, and Jane McIntosh, who are a star!

Is there anything much better than doing meaningful work with amazing friends? Not sure… Thank you to Heidi McWilliams’ #OpensMinds and the @TheADDF for hosting us in #PalmBeach, proud to be members of the board! @MiiaKivipelto #brainhealth

DC's most glamorous Alzheimer's fundraiser is back — the ADDF's Great Ladies Luncheon and Fashion Show returns May 5. 🔗thewashingtonlobbyist.com/addf-great-lad… #AlzheimersResearch #GreatLadiesLuncheon #WashingtonDC #HilarityForCharity #ADDF @TheADDF

A new analysis is challenging the impact of anti-amyloid treatments, pointing to limited cognitive benefit and potential risks. As Laura Nisenbaum, ADDF's Executive Director of Drug Development, noted to @AARP, “Not all drugs in this class are the same.” bit.ly/41AyoqB

More than 85% say they would take an Alzheimer’s blood test if recommended by their physician, according to a study in Alzheimer’s & Dementia. The ADDF has helped drive this progress through our DxA, bringing the first generation of blood tests to market.🔗bit.ly/4sz7EBy

Solving Alzheimer’s is a new Substack from the Alzheimer’s Policy Working Group, featuring insights from frontline clinicians. At the ADDF’s DxA, we’re advancing blood tests and digital tools designed for use in primary care to enable early diagnosis. bit.ly/4srsXVL

Gene therapy is a promising yet complex area of research. At the ADDF, we have long considered ApoE4 a critical target. Now, with growing momentum across the field, there is renewed interest in novel gene therapy strategies aimed at addressing it directly. beingpatient.com/apoe4-targeted…

So, what did MARBLE show? Was CN-105 safe to give to older surgical patients & did it prevent delirium? Stay tuned for the results tomorrow in @JAMANetworkOpen @TheADDF @NIH @ASALifeline @APSForg @snaccprez @SNACCNeuro @Duke_Anesthesia @stanfordanes @AmerDelirium @PeriopCognPIA

Aaron Burstein, ADDF Head of Search & Evaluation, shared with @biospace, how biomarker advances are strengthening the link between biology and clinical outcomes and guiding more targeted treatment decisions. Read More: biospace.com/drug-developme…

Exciting news from @AviadoBio, announcing the ADDF and @AFTDHope strategic investment to advance AVB-101, an investigational gene therapy for people living with #FTD-GRN, and enrollment underway for the fourth cohort of the Phase 1/2 ASPIRE-FTD trial.

Advancing the fight against Alzheimer’s requires progress in both #biology and #diagnostics. DxA 3.0 is advancing next-gen biomarkers for earlier, more precise detection to accelerate drug development and support combination approaches and personalized care for patients. @biogen

The Treat FTD Fund RFP is seeking novel or repurposed therapies & devices in Phase 0–2 trials from #academic and #biotech teams worldwide to advance treatments of #FTD. Both #diseasemodifying and #symptomatic approaches encouraged. @AFTDHope Learn more: bit.ly/3Fs6dP6

We were proud to present the Alzheimer’s Insights Summit 3 alongside our partners at the @AlzData, convening leading researchers and innovators focused on the future of #Alzheimers treatments, #diagnostics, and #AI.